DuPont today announced it has received the Silver Medal from EcoVadis, a global leader in sustainability assessments, in recognition of the company's continued advancement and progress on its ...

Merck & Co. Inc. closed 33.72% short of its 52-week high of $134.63, which the company achieved on June 25th.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

March 11 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid ...

Zebra Technologies (ZBRA) and Merck KGaA (MKKGY) announced a new collaboration aimed at co-creating solutions to address challenges around ...

One of Merck KGaA’s leading immunology assets has flunked the latest part of a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in ...

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

March 5 (Reuters) - Merck's (MRK.N), opens new tab injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics (HALO.O ...